Abstract: Disclosed are a teaching method and a teaching device for improving attention and a computer readable storage medium. The method includes the following operations: obtaining brainwave data of a user collected by an electroencephalograph (EEG) acquisition device, and calculating an attention value according to the brainwave data; switching to a training mode if the attention value is less than a first preset threshold; and obtaining an EEG feature of the user during training, and outputting and displaying an animation effect corresponding to the EEG feature to adjust the user's attention.

Abstract: Training method and apparatus for loan fraud detection model and a computer device are provided, wherein the training method for loan fraud detection model includes: acquiring identity information and user's bank statement information of a plurality of sample users, and fraud label information corresponding to each user; constructing an identity feature vector and a behavior pattern vector according to the identity information; constructing a statement feature vector according to the behavior pattern vector, a second vector transformation matrix and the user's bank statement information; generating a target feature vector according to the behavior pattern vector and the statement feature vector; feeding a target neural network with the target feature vector to acquire a fraud detection result of the target feature vector; and training the target neural network, the first vector transformation matrix and the second vector transformation matrix to obtain a loan fraud detection model.

Abstract: A method for thermally protecting an access point (AP) device may include receiving an actual AP power consumption value, the actual AP power consumption value being one of a plurality of potential AP power consumption values, receiving a sensed internal AP temperature value, the sensed internal AP temperature value being one of a plurality of potential internal AP temperature values, accessing an ambient temperature look up table defining relationships between the plurality of potential AP power consumption values, the plurality of potential internal AP temperature values and a plurality of ambient temperature values, and retrieving one of the plurality of ambient temperature values associated with the actual AP power consumption value and the sensed internal AP temperature value from the ambient temperature look up table, the retrieved ambient temperature value being an estimated ambient temperature value of the AP device.

Abstract: The invention is directed to antibody compositions that specifically bind to polycyclic aromatic hydrocarbons (PAHs) and kits encompassing the same.

Abstract: A maintenance method of a mask plate are provided. The method includes determining determining an abnormality position of the metal coating layer of the mask plate, and determining a coordinate of the abnormality position; coating repairing glue containing a metal material at the abnormality position, so as to flush a plane of the coated glue and a plane of the normal metal coating layer of the mask plate; and curing the repairing glue.

Abstract: A computing device obtains data representing a plurality of items. A viewport is rendered on a display of the computing device. A portion of a first container element and a portion of a second container element are rendered within the viewport. Selectable visual representations for a first subset of the plurality of items are rendered in the portion of the first container element. The computing device receives a plurality of inputs from the user, each of the plurality of inputs selecting a visual representation of an item from the plurality of items rendered in the first container element. Responsive to receiving each input from the user, another visual representation of each selected item is rendered in the second container element, indicating that the selected item has been selected.

Abstract: The present invention relates to an interface and method for enabling interconnection of a host device and a small-formfactor pluggable module. The interface comprises a host device connector operative to receive a mating small-formfactor pluggable module connector and a switching device connected to the host device connector and operative to selectively switch at least one signal carried over the host device connector between at least two separate signal paths of the host device depending on a selected switching mode of the switching device.

Abstract: A system for coordinating transmissions of power line communication (PLC) devices may include a processor and a memory. The processor may be configured to receive channel state information (CSI) from primary PLC devices. The primary PLC devices may be communicatively coupled to secondary PLC devices via collocated power lines, such as bundled power lines. Thus, the transmission of a primary PLC device over a power line to a secondary PLC device may be electromagnetically coupled onto the other power lines, thereby causing far-end crosstalk (FEXT) interference with respect to other secondary PLC devices. The processor may be configured to determine precoding information for compensating for the FEXT interference based at least on the received CSI. The processor may be configured to provide at least a portion of the precoding information to the primary PLC devices and to coordinate precoded transmissions of the primary PLC devices to mitigate the FEXT interference.

Abstract: A server receives a request from a first client device for a file access code. The server generates the file access code, including associating a validity time period with the file access code. The server associates the file access code with a user account at the server and transmits a response to the first client device including the file access code. The server receives, from the first client device, information corresponding to an electronic file. Based on determining that the validity time period for the file access code has not elapsed, the server generates an association between the electronic file and the file access code. The server receives, from a second client device, the file access code. Based on determining that the validity time period of the file access code has not elapsed, the server identifies the electronic file and enables the second client device to access the electronic file.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.

Abstract: The present invention relates to an interface and method for enabling interconnection of a host device and a small-formfactor pluggable module. The interface comprises a host device connector operative to receive a mating small-formfactor pluggable module connector and a switching device connected to the host device connector and operative to selectively switch at least one signal carried over the host device connector between at least two separate signal paths of the host device depending on a selected switching mode of the switching device.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more disease associated with the central nervous system using such compounds or pharmaceutical compostions.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.

Abstract: A system for coordinating transmissions of power line communication (PLC) devices may include a processor and a memory. The processor may be configured to receive channel state information (CSI) from primary PLC devices. The primary PLC devices may be communicatively coupled to secondary PLC devices via collocated power lines, such as bundled power lines. Thus, the transmission of a primary PLC device over a power line to a secondary PLC device may be electromagnetically coupled onto the other power lines, thereby causing far-end crosstalk (FEXT) interference with respect to other secondary PLC devices. The processor may be configured to determine precoding information for compensating for the FEXT interference based at least on the received CSI. The processor may be configured to provide at least a portion of the precoding information to the primary PLC devices and to coordinate precoded transmissions of the primary PLC devices to mitigate the FEXT interference.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula I are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.